In October 2025, the U.S. Food and Drug Administration (FDA) granted approval to multiple new cancer therapies and supportive care options, covering treatments for acute myeloid leukemia (AML), ...
Developers of biosimilars -- medicines that are near-identical copies of biologic drugs -- will no longer be required to conduct clinical trials to prove effectiveness.
UniQure NV's stock plummeted over 54% after the FDA deemed the clinical data for its Huntington's disease gene therapy AMT-130 inadequate. Investors are left questioning the future of the therapy and ...
Shortages to backbone chemotherapy drugs are negatively affecting patient care, and more shortages are likely without policy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback